A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

Diabetes Care
Mehmood A KhanJay L Xue

Abstract

To characterize potential differences in glycemic control, plasma lipid level, and weight in a cohort of patients previously treated with troglitazone (TROG) who were switched to either pioglitazone or rosiglitazone. After a 2-week washout from TROG, 186 patients were randomly assigned to receive either pioglitazone (PIO) or rosiglitazone (ROSI). Weight, HbA(1c), and fasting lipid profile were documented before discontinuing TROG and at 4 months after starting either pioglitazone or rosiglitazone. Secondarily, the effect of concurrent medications on study outcomes was assessed. A total of 127 patients completed follow-up: 67 individuals in the PIO group (32 women, 35 men) and 60 individuals in the ROSI group (33 women, 27 men). There were no significant differences in gender mix, age, weight, fasting lipid profile, or HbA(1c) between the ROSI and PIO groups. After 4 months of randomized treatment, no change in HbA(1c) from baseline between or within groups was noted. Both groups experienced an equal and significant increase in weight from baseline of approximately 2.0 kg. Thiazolidinedione and HMG-CoA reductase inhibitor therapy had significant and independent effects on lipid profile (P < 0.005). Significant improvements in li...Continue Reading

References

Apr 10, 1999·Journal of Clinical Pharmacology·C M LoiA J Sedman
Sep 25, 1999·Clinical Pharmacokinetics·C M LoiJ R Koup
Dec 10, 1999·Diabetes Care·J C Lin, M K Ito
Sep 6, 2000·Journal of Clinical Pharmacy and Therapeutics·L DiTusa, A B Luzier
Nov 30, 2000·Biochemical and Biophysical Research Communications·J SakamotoH Sawada
May 22, 2001·Journal of Clinical Pharmacology·T PrueksaritanontJ D Rogers
Jun 26, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·C G Gegick, M D Altheimer

❮ Previous
Next ❯

Citations

Oct 2, 2009·Current Diabetes Reports·Edoardo Mannucci, Matteo Monami
Jan 1, 2003·Comprehensive Therapy·Biswanath P GoudaVivian A Fonseca
Sep 12, 2002·Trends in Molecular Medicine·Caroline DuvalBart Staels
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
May 1, 2004·Diabetes Technology & Therapeutics·Shanti Serdy, Martin J Abrahamson
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Sunil AsnaniVivian A Fonseca
Jul 27, 2007·Journal of Medicinal Food·Sarah Rachel KatzEphraim Philip Lansky
Jun 16, 2009·Cardiology in Review·Irene A WeissMonica D Schwarcz
Aug 27, 2010·Current Opinion in Lipidology·Martijn C G J BrouwersAnton F H Stalenhoef
May 29, 2008·Diabetes, Obesity & Metabolism·E MannucciN Marchionni
Jul 21, 2009·Diabetes, Obesity & Metabolism·G CharpentierUNKNOWN F-PIO-100 Study Investigators
Apr 13, 2010·Diabetes, Obesity & Metabolism·Kevin Niswender
Oct 1, 2010·Diabetes, Obesity & Metabolism·E E WrightR M Cuddihy
Apr 28, 2005·International Journal of Clinical Practice·J William Lester, A W Fernandes
Jun 28, 2007·International Journal of Clinical Practice. Supplement·G Derosa
Jun 6, 2009·International Journal of Clinical Practice·G Schernthaner
Jun 30, 2012·PPAR Research·Angélica Amorim Amato, Francisco de Assis Rocha Neves
Mar 10, 2007·PPAR Research·Pascal Froment, Philippe Touraine
May 21, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tunghi M PiniHarvey J Murff
Dec 22, 2010·Lipids in Health and Disease·Krishnaswami Vijayaraghavan
Mar 12, 2004·Drugs & Aging·Rukmini RajagopalanFrederick T Murray
Jul 3, 2002·Drugs·Fabrice M A C MartensTon J Rabelink
Oct 17, 2006·Drugs·Emma D Deeks, Lesley J Scott
Feb 24, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Amit Khera, Darren K McGuire
Sep 29, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Giuseppe Derosa
Nov 24, 2007·Pharmacogenomics·Sharon Cresci
Jun 3, 2005·Clinical Medicine & Research·Michael T Sheehan
May 15, 2013·Future Cardiology·Timothy RaymondA Michael Lincoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.